DREADD
Designer receptors exclusively activated by designer drugs (DREADDs) are genetically engineered GPCRs that are activated by physiologically inert synthetic small molecules (designer drugs) but not their endogenous ligand. Read our DREADDs mini-review or for practical advice on using these ligands in the lab see Stability of Water-Soluble DREADD Ligands in Solution: A Technical Review and Clozapine N-Oxide (freebase) - a technical review on stability, solubility and use in the lab).
Clozapine (HB1607)
Description:Prototypic, atypical antipsychotic, binds to both serotonin and dopamine receptors
Purity:>99%
- Description:
Water soluble prototypic, atypical antipsychotic. Binds to both serotonin and dopamine receptors.
Purity:>98%
-
Clozapine N-oxide (CNO) (freebase) (HB1807)
Description:Prototypical DREADD activator. Clozapine metabolite.
Purity:>98%
- Description:
Dihydrochloride salt of CNO - the prototypical DREADD activator
Purity:>98%
-
Deschloroclozapine (DCZ) (HB8555)
Description:Potent, selective and metabolically stable hM3Dq and hM4Di muscarinic DREADD actuator.
Purity:>98%
- Description:
Potent, selective and metabolically stable hM3Dq and hM4Di muscarinic DREADD actuator. Water soluble.
Purity:>99%
- Description:
Effective agonist for muscarinic-based DREADDs in vitro and in vivo. Non-CNO chemogenetic actuator. Brain penetrant. Water soluble.
Purity:>98%
-
DREADD agonist 21 (Compound 21) (HB4888)
Description:Effective agonist for muscarinic-based DREADDs in vitro and in vivo. Non-CNO chemogenetic actuator. Brain penetrant.
Purity:>98%
-
Iperoxo (HB9785)
Description:Potent muscarinic acetylcholine receptor superagonist. Also binds the hM3R-miniGq DREADD receptor.
-
JHU37152 (DREADD ligand) (HB6252)
Description:Novel DREADD agonist with high affinity and potency for hM3Dq and hM4Di. Active in vivo. Freebase.
Purity:>98%
